arrow
T

Tushar Kotecha

University of London
H指数:32
被引数:4,820

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Myocardial Amyloid Burden in Transthyretin Amyloidosis

转甲状腺素蛋白淀粉样变性中的心肌淀粉样蛋白负荷

JACC
IF0
2025-11-080
OAAI
Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance

Patel, R.K.; Ioannou, A.; Sheikh, A.; Razvi, Y.; Mansell, J.; Martinez-Naharro, A.; Knight, D.; Kotecha, T.; Porcari, A.; Chacko, L.; 等. 甲状腺素转运蛋白淀粉样变性心肌病:基于心血管磁共振的自然病程及治疗反应评估。Eur. Heart J. 2025, ehaf412. [Google Scholar] [CrossRef] [PubMed]

2025-07-014
OAAI
Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI Results From the ORBITA-2 Trial

多巴酚丁胺应激超声心动图显示的缺血可预测PCI疗效——ORBITA-2试验结果

2025-05-011
PRE
Metformin associates with higher myocardial perfusion reserve and survival in type 2 diabetes mellitus patients
2024-11-081
OAAI
The Impact of Bariatric Surgery on Coronary Microvascular Function Assessed Using Automated Quantitative Perfusion CMR
2024-11-011
PRE
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
2024-11-010
OAAI
Microvascular obstruction in cardiac amyloidosis

心脏淀粉样变性的微血管阻塞

2024-10-180
OA
Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial

冠状静脉窦减少剂治疗难治性心绞痛 (ORBITA-COSMIC): 一项随机,安慰剂对照试验

LANCET
IF88.5
2024-04-0111
OAAI
Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis
2024-02-208
OAAI
Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?

p.(V142I) 相关变异型甲状腺素运载蛋白淀粉样心肌病的深度表型: 与野生型甲状腺素运载蛋白淀粉样变性不同?

2024-01-2810
OA
Myocardial perfusion in cardiac amyloidosis
2024-01-216
OA
A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina

经皮冠状动脉介入治疗稳定型心绞痛的安慰剂对照试验

2023-12-2160
OAAI
Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance
2023-12-185
OA
Redefining Cardiac Involvement in Systemic Immunoglobulin Light Chain Amyloidosis and Treatment Implications
2023-11-070
PRE
Incremental Value of Abnormal Quantitative Myocardial Perfusion and Myocardial Infarction Using Cardiovascular Magnetic Resonance as Prognostic Markers in Type 2 Diabetes Mellitus
2023-11-070
PRE
Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping
2023-09-0114
OAAI